On April 23, the FDA and CMS jointly launched the Regulatory Alignment for Predictable and Immediate Device pathway, a Medicare coverage program that lets a proposed national coverage determination be issued the same day a breakthrough device receives FDA marketing authorization. Under the prior model, hospitals could not be confident a Medicare patient would be reimbursed for a newly cleared breakthrough device for roughly a year. Under RAPID, that gap can compress to two months. If you are building a company in surgical robotics, advanced interventional devices, or any breakthrough-eligible category, this single program just rewrote the timing math for the entire commercial side of your business. The companies that finish in this environment will be the ones whose operating model assumes the new timeline rather than defaulting to the old one.
If You Are Building a Company in This Environment
The default founder operating model for a breakthrough-eligible medical device company has been built around a year-long gap between FDA clearance and meaningful Medicare coverage. The gap shapes everything. The capital plan funds 12 to 18 months of post-clearance commercial activity against revenue that hospitals cannot yet recover at scale. The salesforce hires staff trained to do clinical evangelism with hospital innovation committees rather than transact volume with procurement. The marketing budget allocates against awareness and physician training rather than coverage-driven adoption. The reimbursement function operates as a parallel campaign against CMS and the MACs, often staffed late and underfunded relative to its load-bearing role in the commercial outcome.
That model is now describing a market that no longer exists for breakthrough-eligible companies. RAPID does not eliminate the work, but it changes the gating function. The company that can move from FDA marketing authorization to Medicare coverage in 60 to 90 days has a fundamentally different commercial profile than one that runs on the old 12-month gap. Capital efficiency improves. Salesforce productivity improves. The economics of the launch shift from a long-funded commercial campaign to a sharper, faster ramp into volume revenue. Founders who notice this and rebuild their operating model around it will outpace founders who run the prior playbook against the new pathway.
The hardest part of this is recognizing that the change is real and not just a regulatory press release. CMS and FDA have built joint pathways before that did not deliver in practice. RAPID is structurally different because the same-day proposed national coverage determination is a binding administrative commitment, not a coordination protocol. The mechanism is in place. The first cohort of devices is identified. The work for founders is to figure out whether your device is in scope and what your operating model looks like if it is.
The Mistake That Turns Breakthrough Founders Into Pre-Coverage Companies
The most common pattern that breaks first-time medtech founders in the breakthrough device category is treating the FDA pathway as the financing milestone and the reimbursement work as a downstream commercial issue. The pattern is logical. The FDA milestone is more visible to investors, more defensible against competitors, and more measurable inside the company. The reimbursement work is harder to translate into a slide. The default is to defer it.
Under the prior coverage timeline, the deferral had a year-long forgiveness window built into it. A company that finished the FDA work and then started the serious reimbursement work post-clearance could often get to a workable Medicare position by the time commercial volume needed to scale. The market was tolerant of the sequencing because there was time. RAPID compresses that tolerance. A company that does not have its coverage strategy, its evidence package, and its CMS engagement in motion before FDA clearance now arrives at an FDA milestone and finds that the new pathway it could have qualified for has already passed by, because the joint coordination with CMS was supposed to begin during FDA review, not after.
The conversion from breakthrough founder to pre-coverage company is the most expensive pattern in this segment of the market. The capital you raised against an FDA milestone now has to fund a slower commercial ramp than the RAPID-aligned competitor next door. The salesforce you hired against a 12-month gap now competes for hospital procurement attention with a competitor whose Medicare position cleared inside the first quarter of launch. The pattern is recoverable, but the recovery costs a year of runway and a market position that is harder to defend than the one a properly sequenced launch would have produced.
What Finishing the Coverage Work Looks Like Before Clearance
The companies that win in the new pathway will do specific things during FDA review that most teams treat as too early. They will engage CMS coverage staff in the TAP framework or its breakthrough-equivalent process during FDA review, not after, so that the agency understands the device, the population, and the evidence base in time to issue a same-day proposed national coverage determination. They will build their clinical-economic evidence package on the same trajectory as their FDA evidence package, with the same rigor, against the same statistical thresholds. They will design their pivotal trials with Medicare-relevant subgroups and reimbursement-grade comparators, even when the FDA endpoints would have permitted weaker design choices.
They will sequence their hospital launch sites with procurement readiness in mind from the first conversation. The 510(k) pattern of the past, where commercial launch sites were chosen on the basis of clinical champions and surgeon enthusiasm, leaves the procurement coordination unfinished at the moment the device clears. In the RAPID environment, the launch site that has its procurement contracting, capital line approval, and reimbursement readiness in place at clearance is operationally much further forward than the launch site selected primarily for clinical interest. Both matter. The mistake is treating only one of the two as the qualifier.
For startups, the equivalent move at smaller scale is to identify which two or three Medicare-relevant evidence questions the coverage decision will turn on, and finish those questions to a depth that survives a coverage-decision review before the FDA pathway concludes. The clinical-economic story has to be done at the level of the comparator the coverage analyst will care about, not at the level of the indication the FDA reviewer will care about. The two are related and not identical.
The Five Questions When the Reimbursement Window Compresses
The five-question framework in Founders Who Finish reframes the work that determines whether a company makes it as a sequence of decisions about what is actually finished and who gets to say so. RAPID changes the timing of every one of those questions for breakthrough-eligible devices.
Question 1
What are you actually finishing?
If your definition of done stops at FDA marketing authorization, you are not finishing the company anymore. The cleared device with a same-day Medicare coverage decision is the new completion state for a breakthrough-eligible launch. Founders who finish are working on both halves of that completion state in parallel during FDA review. Founders who treat the coverage decision as a post-clearance activity will arrive at the FDA milestone and discover that the runway gain they could have captured has already shifted to a faster competitor.
Question 2
Who decides you are done?
In the RAPID pathway, the coverage analyst at CMS is now a co-decider with the FDA reviewer, on a timeline that overlaps the FDA pathway. Founders who finish have built a working relationship with the coverage staff during FDA review, not after. That relationship has nothing to do with lobbying; it is the same kind of evidence-grounded engagement the FDA review requires, run in parallel with a different audience whose decision criteria are clinical-economic rather than safety-and-effectiveness alone.
Question 3
What does your evidence actually prove?
FDA evidence proves the device is safe and effective for the cleared indication. Medicare coverage evidence proves the device is reasonable and necessary for the Medicare beneficiary population. The two evidence bases overlap, but the overlap is not the whole story. Founders who finish in the RAPID environment have a coverage-grade evidence package built into their pivotal trial design, not a coverage-grade evidence package generated post-clearance against a competitor that already cleared and already has data.
Question 4
What does your path to reimbursement look like?
The same-day proposed national coverage determination is not the end of the reimbursement story. Coding, payment levels, and MAC engagement still have to be worked, on a faster timeline than the prior model assumed. Founders who finish have a reimbursement function staffed at clearance, with the coding strategy, the payment-level case, and the MAC engagement plan already in motion. The pathway that compresses coverage timing also compresses the operational time available to set up the reimbursement infrastructure that the coverage decision activates.
Question 5
What does the finish line look like to an acquirer?
Strategic acquirers of breakthrough-eligible device companies pay premiums for cleared devices with Medicare coverage in place. Under the prior model, that combination usually arrived a year apart, and the acquirer either bought into the gap or paid the discount associated with it. RAPID changes the math. A company that arrives at the acquirer with both authorizations in place inside the same quarter is a structurally different asset than a company arriving with only the FDA authorization and a year of coverage work ahead. Founders who finish are positioning their companies to land in that first category, not the second.
Founders Who Finish
The guide for founders building in regulated markets
The five-question framework for building medical device, surgical robotics, and advanced interventional companies that finish what they start, in the regulatory and reimbursement environment as it actually exists.
Get the Book